Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registry

Abstract

Purpose Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome emerging from a deregulated immune response due to various triggers. In adults, systematic data are sparse, which is why recommendations on diagnosis and management have been adopted from pediatric guidelines. A nationwide clinical registry with associated consulting service as collaborative initiative of HLH-specialized pediatricians and hematologists was initiated to better characterize HLH in adults. Methods Patients with proven or suspected HLH were registered by 44 institutions. Both HLH-2004 diagnostic criteria and the HScore (www.saint antoi ne.aphp.fr/score /) were used to confirm HLH diagnosis. Data referring to underlying disease, treatment, outcome, clinical presentation and laboratory findings were recorded. Results The study included 137 patients and provides the first systematic data on adult HLH in Germany. Median age was 50 years with a wide range (17-87 years), 87 patients (63.5%) were male. Most common triggering diseases were infections in 61 patients (44.5%) and malignancies in 48 patients (35%). Virtually all patients had elevated ferritin concentrations, and 74% had peak concentrations greater than 10,000 µg/l. At time of analysis, 67 of 131 patients (51%) had died. Patients with malignancy-associated HLH had the shortest median survival (160 days), however no statistically significant difference between subgroups was observed (p = 0.077). Platelets under 20*10 9 /l and low albumin concentrations (< 20 g/l) were associated with poor overall and 30-day survival. Conclusion Close multidisciplinary case consultation and cooperation is mandatory when treating adult HLH patients. Early contact with reference centers is recommended, especially in relapsing or refractory disease.

COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy

“…The hyperferritinemic syndrome pathogenesis is extremely complex and variable. Genetic mutations, infections, underlying diseases and immunosuppression can play a distinct role in these conditions, leading to the unique epilogue that is hyperferritinemia (> 500 μg/L) and hyperinflammation [ 29 ]. According to Schulert et al [ 30 ], despite the numerous protagonists that can play a role in the development of hyperferritinemic syndrome, they might converge in at least two mechanisms that provoke hyperferritinemia: overactivation of T lymphocytes and over-activity of IFN-γ [ 30 ].…”

Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation

“…Ergänzend zeigte als Surrogat der lymphozytären Aktivierung der sIL2R eine im Median 2‑fache Erhöhung über den oberen Normwert (1519 U/ml (285–7192)). Beide, Ferritin und sIL2R, lagen damit deutlich unterhalb der für die hämophagozytische Lymphohistiozytose oder das Makrophagen-Aktivierungssyndrom bekannt exzessiv erhöhten Werte [ 4 ], reihen sich jedoch gut in hyperferritinämische Inflammation bei Sepsispatienten ein [ 18 ].…”

Frequently asked questions regarding SARS-CoV-2 in cancer patients—recommendations for clinicians caring for patients with malignant diseases

“…Recent reports support a relevant proportion of hyperinflammation in severe cases of COVID-19 and suggest the consideration of additional anti-inflammatory drugs like tocilizumab or ruxolitinib in patients fulfilling the criteria of HLH [1,[37][38][39]. Also, because of the increased incidence of pulmonary embolism, anticoagulation is strongly recommended [40].…”